Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world

Grille, Sofía; Iastrebner, Marcelo; Lorand-Metze, Irene; Velden, Vincent van der; Ikoma, Maura Rosane Valério; Vidal-Senmache, Gabriela; Colado, Enrique; Rabelo-Carrasco, L.J.; Blanco, Alfonso; Huamán-Garaicoa, Fuad; O’Connor, José-Enrique; Pochintesta, C. Cao; Jensen, Evan; Bacal, Nydia Strachman; Díaz, Lilián; Lens, Daniela

doi:10.1016/j.leukres.2019.01.009

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple reports from various countries have confirmed the diagnostic value of i MDSFlow recommendations (Chauhan et al, 2021 ; Cremers et al, 2016 ; Cremers et al, 2017 ; Davydova et al, 2021 ; Grille Montauban et al, 2019 ; Majcherek et al, 2021 ; Porwit & Rajab, 2015 ; Takeuchi et al, 2020 ). However, results of a survey concerning current MFC practice in 229 laboratories around the world showed that although many laboratories used large numbers of markers in MFC workup of MDS (median: 20 ± 4.5), the compliance with i MDSflow recommendations was low, and proposed scoring systems were not widely applied (Grille Montauban et al, 2019 ; Jensen et al, 2019 ). With the hope of increasing the harmonization of MFC MDS diagnostics, the current paper presents a summary of the progress in this field and an update on consensus i MDSFlow guidelines for the assessment of significant anomalies in various bone marrow (BM) cell compartments for MFC features of dysplasia as a part of a special Issue of Clinical Cytometry B, focused on MFC applications in MDS and MDS/MPN (Kern et al, 2022 ; van de Loosdrecht et al, 2023 ; van der Velden et al, 2023 ; Wagner‐Ballon et al, 2023 ; Westers et al, 2021 ; Westers et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Porwit

Béné

Duetz

et al. 2022

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34 + CD19 À ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machinelearning-based analytical tools of interest should be applied in parallel to

show abstract

Section: Introductionmentioning

confidence: 99%

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Porwit

Béné

Duetz

et al. 2022

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, the application of iFS is labor-intensive and time-consuming. A survey evaluating the current FCM practice for the diagnosis of MDS in 229 laboratories worldwide showed that the usage of any FCM scoring system was very limited [ 22 ]. This result reflects that calculating the scores is hardly compatible with the routine clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

Plander,

Kányási,

Szendrei

et al. 2024

Pathol. Oncol. Res.

View full text Add to dashboard Cite

BackgroundMyelodysplastic neoplasms (MDS) are characterized by cytopenia, morphologic dysplasia, and genetic abnormalities. Multiparameter flow cytometry (FCM) is recommended in the diagnostic work-up of suspected MDS, but alone is not sufficient to establish the diagnosis. Our aim was to investigate the diagnostic power of FCM in a heterogeneous population of patients with cytopenia, excluding cases with increased blast count.MethodsWe analyzed bone marrow samples from 179 patients with cytopenia (58 MDS, 121 non-MDS) using a standardized 8-color FCM method. We evaluated the sensitivity, specificity, and accuracy of several simple diagnostic approaches, including Ogata score, extended Ogata score, the WHO and ELN iMDSFlow recommended “3 aberrations in two cell compartments method,” and the combination of the Ogata score and “3 aberrations in two cell compartments method.” The patients were followed until the diagnosis was confirmed, with a median follow-up of 2 months (range 0.2–27).ResultsThe combination of Ogata score and “3 aberrations in two cell compartments method” achieved the highest diagnostic accuracy (78%) with sensitivity and specificity 61% and 86%, respectively. When using only the “3 aberrations in two cell compartments method,” the accuracy was 77% with a sensitivity of 72% and a specificity of 79%. The most frequently observed etiologies among the false positive cases were substrate deficiencies, inflammation/infection, or toxic effects. MDS can be excluded in all these cases after a thorough clinical evaluation and a relatively short follow-up.ConclusionFCM remains an important but supplementary part in an integrated diagnostic process of MDS with low blasts. The combination of the Ogata score and the “3 aberrations in two cell compartments method” slightly improves accuracy compared to the detection of “3 aberrations in two cell compartments method” alone.

show abstract

The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study

et al. 2021

View full text Add to dashboard Cite

Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world

Cited by 4 publications

References 25 publications

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study

Contact Info

Product

Resources

About